Marvel Biosciences Corp. Announces Change of Chief Financial Officer

Calgary, Alberta--(Newsfile Corp. - February 1, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") is pleased to announce the appointment of Harry Nijjar, CPA, CMA, as Chief Financial Officer of the Company, effective February 1, 2022, replacing Preston Maddin who left the Company effective January 31, 2022.

Mr. Nijjar joined Malaspina Consultants Inc. in 2011 and is currently a Managing Director. Malaspina Consultants Inc. has been engaged by the Corporation to provide CFO, operational accounting and strategic financial advisory services. Mr. Nijjar has worked extensively with public companies across various industries, helping them navigate the regulatory and financial reporting environment.

Rod Matheson, Chairman and Chief Executive Officer, stated: "We feel very fortunate to have Harry's wide-ranging financial management expertise as we continue to execute our strategic plans for 2022. We also want to thank Preston for his invaluable service during his time with the Company. We wish him the very best in his future endeavours."

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081

Email: [email protected]

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403-770-2469

Email: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112218

You May Also Be Interested In

• Goldcana Grants Incentive Stock Options
• Avis Budget Group, Inc. Notice of September 29, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and Approximately 29% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick